Bayer Consumer Health Recovery Rides Allergy, Dermatology Brand Sales
Executive Summary
Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.
You may also be interested in...
People On The Move: Appointments At Stada, Bayer and Anses
Stada hires Accord's Romaniszyn to lead its business in Poland; Bayer extends the contract of chairman Werner Baumann; and France's Anses appoints a new chair of the board.
Bayer To Settle Monsanto Litigation, Remains Prepared To Invest For Growth
The health care and crop science conglomerate will pay up to $10.9bn to resolve most Roundup claims, but still has capital to do bolt-on deals like last year’s BlueRock cell therapy buy.
Bayer Sees Light At End Of Consumer Turnaround Tunnel: Q3 Sales Grow 3.7%
Bayer consumer health segment shows 3.7% growth to $1.43bn on 9% growth in pain relief and 6.4% in allergy and cold. But North American business still faces challenges.